Quaternary Cu2ZnSnSe4 thin films for solar cells applications

Polycrystalline thin films of Cu2ZnSnSe4 (CZTSe) were produced by selenisation of Cu(Zn,Sn) magnetron sputtered metallic precursors for solar cell applications. The p-type CZTSe absorber films were found to crystallize in the stannite structure (a = 5.684 Ã… and c = 11.353 Ã…) with an electronic bandgap of 0.9 eV. Solar cells with the structure were fabricated with device efficiencies up to 3.2%

Dental X-Ray Exposure The Past has become the Future

Most dental X-ray procedures are delegated to office staff and some recommendations and techniques, such as selection criteria and rectangular collimation for intraoral imaging, have been ignored or forgotten by some dentists. Some of the X-ray exposure recommendations, updated by the American Dental Associtation’s Science Institute in June 2018, and the need to adopt guidelines proposed by the public campaign Image Gently are discussed to help the reader develop safe X-ray protocols, from intraorals to CBCT

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.

PurposeCabozantinib is a multi-kinase inhibitor that targets MET, AXL, and VEGFR2, and may synergize with EGFR inhibition in NSCLC. Cabozantinib was assessed alone or in combination with erlotinib in patients with progressive NSCLC and EGFR mutations who had previously received erlotinib.MethodsThis was a phase Ib/II study (NCT00596648). The primary objectives of phase I were to assess the safety, pharmacokinetics, and pharmacodynamics and to determine maximum tolerated dose (MTD) of cabozantinib plus erlotinib in patients who failed prior erlotinib treatment. In phase II, patients with prior response or stable disease with erlotinib who progressed were randomized to single-agent cabozantinib 100 mg qd vs cabozantinib 100 mg qd and erlotinib 50 mg qd (phase I MTD), with a primary objective of estimating objective response rate (ORR).ResultsSixty-four patients were treated in phase I. Doses of 100 mg cabozantinib plus 50 mg erlotinib, or 40 mg cabozantinib plus 150 mg erlotinib were determined to be MTDs. Diarrhea was the most frequent dose-limiting toxicity and the most frequent AE (87.5% of patients). The ORR for phase I was 8.2% (90% CI 3.3-16.5). In phase II, one patient in the cabozantinib arm (N = 15) experienced a partial response, for an ORR of 6.7% (90% CI 0.3-27.9), with no responses for cabozantinib plus erlotinib (N = 13). There was no evidence that co-administration of cabozantinib markedly altered erlotinib pharmacokinetics or vice versa.ConclusionsDespite responses with cabozantinib/erlotinib in phase I, there were no responses in the combination arm of phase II in patients with acquired resistance to erlotinib. Cabozantinib did not appear to re-sensitize these patients to erlotinib

A survey of equipment and instrumentation regarding use, undesirable aspects and new designs desired by northwest optometrists

A survey of equipment and instrumentation regarding use, undesirable aspects and new designs desired by northwest optometrist

Student experiences and perceptions of compulsory research projects: a veterinary perspective

Background Although research underpins clinical work, many students training to be clinicians are not inherently interested in developing research skills. Aim To characterise and understand veterinary student experiences and perceptions of compulsory research projects. Methods This was an explanatory sequential mixed-methods study, with a questionnaire survey of an entire cohort informing purposive selection for focus group discussions. Student views were triangulated with staff questionnaire data. Results About a third of the cohort felt that the project had not been worthwhile or had not fostered useful skills. Focus group data analysis identified fragility of motivation and lack of clear schemata for the research process as key themes. Students were easily demotivated by typical research challenges and lack of schemata contributed to a poor understanding of the rationale for the project, encouraging highly extrinsic forms of motivation. Triangulation with staff questionnaire data indicated that staff understood students’ challenges, but were more likely than students to consider it to be a valuable learning experience. Conclusions Findings support ongoing curriculum development and emphasise that, to optimise motivation, engagement and learning, students training to be clinicians need a clear rationale for research, based on development of critical inquiry skills as a core clinical competency

TRAPHIC - Radiative Transfer for Smoothed Particle Hydrodynamics Simulations

We present TRAPHIC, a novel radiative transfer scheme for Smoothed Particle Hydrodynamics (SPH) simulations. TRAPHIC is designed for use in simulations exhibiting a wide dynamic range in physical length scales and containing a large number of light sources. It is adaptive both in space and in angle and can be employed for application on distributed memory machines. The commonly encountered computationally expensive scaling with the number of light sources in the simulation is avoided by introducing a source merging procedure. The (time-dependent) radiative transfer equation is solved by tracing individual photon packets in an explicitly photon-conserving manner directly on the unstructured grid traced out by the set of SPH particles. To accomplish directed transport of radiation despite the irregular spatial distribution of the SPH particles, photons are guided inside cones. We present and test a parallel numerical implementation of TRAPHIC in the SPH code GADGET-2, specified for the transport of mono-chromatic hydrogen-ionizing radiation. The results of the tests are in excellent agreement with both analytic solutions and results obtained with other state-of-the-art radiative transfer codes.Comment: 31 pages, 20 figures. Accepted for publication in MNRAS. Revised version includes many clarifications and a new time-dependent radiative transfer calculation (fig. 19

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC. Aim of this research was to study the prognostic and predictive value of tumor (MET, the receptor tyrosine kinase encoded by the homonymous MNNG-HOS transforming gene) and circulating (MET, hepatocyte growth factor [HGF], alpha-fetoprotein [AFP], vascular endothelial growth factor [VEGF]) biomarkers in second-line HCC. Tumor MET-High status was centrally assessed by immunohistochemistry. Circulating biomarkers were centrally analyzed on serum samples collected at baseline and every 4-8 weeks, using medians as cut-off to determine High/Low status. Tumor MET, tested in 77 patients, was more frequently High after (82%) versus before (40%) sorafenib. A significant interaction (p = 0.04) between tivantinib and baseline tumor MET in terms of survival was observed. Baseline circulating MET and HGF (102 patients) High status correlated with shorter survival (HR 0.61, p = 0.03, and HR 0.60, p = 0.02, respectively), while the association between AFP (104 patients) or VEGF (103 patients) status and survival was non-significant. Conclusions: Tumor MET levels were higher in patients treated with sorafenib. Circulating biomarkers such as MET and HGF may be prognostic in second-line HCC. These results need to be confirmed in larger randomized clinical trials